SCHEMBL1132048

SCHEMBL1132048

CC/C(=C(/C)C(=O)O)c1cc(C2CCCCC2)n(-c2ccc(OCc3ccccc3)cc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 2/20 0.45
BCL2 P10415 1/20 0.44
MCL1 Q07820 1/20 0.44
KDM4E B2RXH2 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HRH3 Q9Y5N1 4/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
CHRNB2 P17787 1/20 0.38
CHRNA5 P30532 1/20 0.38
CHRNA7 P36544 1/20 0.38
CHRNA4 P43681 1/20 0.38
CRACR2A Q9BSW2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAOB P27338 1/20 0.38
NPY1R P25929 1/20 0.38
KCNH2 Q12809 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1131660 1.00 MDM2 (0.45) MDM2BCL2MCL1KDM4ESMN1; SMN2
SCHEMBL1132014 0.86 SLC5A1 (0.37) CRACR2A
SCHEMBL1132075 0.86 MDM2 (0.60) MDM2BCL2MCL1KDM4ESMN1; SMN2
SCHEMBL1132016 0.86 SLC5A1 (0.37) CRACR2A
SCHEMBL1131475 0.84 FAAH (0.52) MDM2BCL2MCL1KMT2AALDH1A1
SCHEMBL1131836 0.84 MDM2 (0.46) MDM2BCL2MCL1KDM4ESMN1; SMN2
SCHEMBL1131756 0.81 KDM4E (0.43) MDM2BCL2MCL1KDM4ESMN1; SMN2
SCHEMBL1132002 0.81 KDM4E (0.43) MDM2BCL2MCL1KDM4ESMN1; SMN2
SCHEMBL1131833 0.79 MDM2 (0.47) MDM2BCL2MCL1KDM4ESMN1; SMN2
SCHEMBL1131835 0.79 MDM2 (0.47) MDM2BCL2MCL1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663105-B1 CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS BRISTOL MYERS SQUIBB CO (US) 2011-02-16 EP claimed
EP-1663105-B1 CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS BRISTOL MYERS SQUIBB CO (US) 2011-02-16 EP disclosed